Price T Rowe Associates Inc Agios Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,423,537 shares of AGIO stock, worth $81.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,423,537
Previous 2,832,512
14.44%
Holding current value
$81.8 Million
Previous $126 Million
36.72%
% of portfolio
0.01%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding AGIO
# of Institutions
244Shares Held
59.9MCall Options Held
270KPut Options Held
332K-
Farallon Capital Management LLC San Francisco, CA5.67MShares$192 Million0.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$190 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$164 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.52MShares$119 Million2.3% of portfolio
-
Armistice Capital, LLC New York, NY2.26MShares$76.4 Million1.05% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $1.85B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...